Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus DOXY 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus DOXY 200.
AUREOMYCIN vs DOXY 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
200 mg orally once daily or 100 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic